Financial

Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023

PONTE VEDRA, Fla., Feb. 8, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive Officer, Quang Pham, and other Cadrenal team members will ring the Nasdaq Stock Market closing bell […]

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2023

PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of January 31, 2023 (pursuant to Article L. 233-8 II of the […]

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on February 1, 2023, the Compensation Committee of […]

Acticor Biotech Announces the Appointment of Patricia Zilliox to the Board of Directors as an Independent Director

PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, is announcing today the appointment of Patricia Zilliox as an independent director to replace Corinne Le Goff, whose plurality of […]

Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer

LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the appointment of J.P. Gabriel as Chief Technical Operations Officer following the retirement of Jørgen Wittendorff, SVP, Technical Operations. In […]

TransMedics Appoints Nick Corcoran as Senior Vice President of Supply Chain and Operations

ANDOVER, Mass., Feb. 2, 2023 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Nick Corcoran as Senior Vice President of Supply Chain and Operations, effective immediately. “Nick has extensive end-to-end supply chain and […]

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

CHAPEL HILL, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today the pricing of a public offering of (i) 8,666,666 shares of its common […]

Integer Holdings Corporation Reduces Borrowing Costs with Closing of $500 million of Convertible Senior Notes Offering

~ Strategic transaction to meaningfully reduce interest expense ~ ~ Immediately earnings accretive in 2023 ~ PLANO, Texas, Feb. 03, 2023 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR) (the “Company”), a leading medical device outsource manufacturer, announces the closing of its offering of $500 million aggregate principal amount of […]